Topics

Posted 9/7/2023, 3:39:00 PM

Weight-Loss Drug Market Can Hit $100 Billion, J.P. Morgan Says. That Makes Eli Lilly Stock a Big Winner.

J.P. Morgan estimates weight-loss drug market could reach $100 billion annually by 2030
Eli Lilly could hit $50 billion in annual sales from weight-loss drugs by 2030
Eli Lilly seen as major winner from growth of obesity treatments
Weight-loss drugs like tirzepatide expected to drive growth
Article discusses outlook for Eli Lilly stock based on obesity drug potential

barrons.com

Relevant topic timeline:

9/5/2023

Weight-Loss Drug Stocks Are Soaring. Why There’s More Room to Run.

Weight-loss drugs are becoming increasingly popular and are expected to have a significant impact on the pharmaceutical industry.

9/11/2023

Pharma Market Boom Coming: TBRC Reports Reveal $3 Trillion Industry by 2030 Driven by Disease, Healthcare Advances

The pharmaceutical market is expected to grow significantly by 2030, reaching $3,206 billion, driven by advances in healthcare technologies, increasing healthcare expenditures, and the rise of chronic diseases. The Business Research Company offers comprehensive reports to assist pharmaceutical companies with informed decision-making and staying competitive in this dynamic sector.

9/16/2023

Eli Lilly Poised for Massive Growth with Diabetes, Obesity Drugs and Potential Alzheimer's Blockbuster

Eli Lilly, a biotech giant known for its work in diabetes and obesity care, has the potential to provide a CAGR of nearly 16% and turn an initial investment of $1,000 into $2,500 by 2030, driven by its strong growth in the therapeutic area and promising pipelines in other fields like Alzheimer's disease.

9/19/2023

Eli Lilly Sues Providers Over Unauthorized Sales of Diabetes Drug Mounjaro Amid Shortage

Eli Lilly has sued 10 medical spas, wellness clinics, and compounding pharmacies across the U.S. for allegedly selling unauthorized versions of its diabetes drug Mounjaro, as the company faces a shortage of the drug due to high demand and its off-label use for weight loss.

9/20/2023

New Obesity Drugs Could Transform Health but Disrupt Major Industries

Anti-obesity drugs developed by Novo Nordisk and Eli Lilly have the potential to transform public health but could also disrupt industries such as food, fitness, and healthcare, affecting companies like Nestlé and McDonald's.

9/22/2023

Obesity Drug Market Set to Boom as New Medications Gain Traction

The global market for weight-loss drugs is projected to reach $100 billion by 2035, with revenue in the US potentially reaching as high as $70 billion alone.

9/29/2023

Spending on Ads for Diabetes Drugs Jumps 20% in 2022, Totaling Nearly $500 Million

Drugmakers spent nearly $500 million on advertisements for obesity and diabetes treatments in the U.S. during the first seven months of this year, with Novo Nordisk's Ozempic and Wegovy leading the pack.

9/29/2023

Structure Therapeutics Stock Jumps on Positive Data for Experimental Obesity Pill

Shares of Structure Therapeutics surged more than 30% as their experimental obesity pill demonstrated success in helping participants lose an average of 10 pounds in a small early-stage trial, positioning it to potentially compete in the booming obesity drug market.

10/3/2023

Lilly to Acquire POINT Biopharma for $1.4 Billion, Gaining Radioligand Cancer Therapies

Eli Lilly will acquire POINT Biopharma, a radiopharmaceutical company, in a deal worth $1.4 billion, aiming to develop radioligand therapies for cancer treatment by precisely targeting cancer cells while limiting damage to healthy tissue.

Topics

Posted 9/7/2023, 3:39:00 PM

Weight-Loss Drug Market Can Hit $100 Billion, J.P. Morgan Says. That Makes Eli Lilly Stock a Big Winner.

J.P. Morgan estimates weight-loss drug market could reach $100 billion annually by 2030
Eli Lilly could hit $50 billion in annual sales from weight-loss drugs by 2030
Eli Lilly seen as major winner from growth of obesity treatments
Weight-loss drugs like tirzepatide expected to drive growth
Article discusses outlook for Eli Lilly stock based on obesity drug potential

barrons.com

Relevant topic timeline:

9/5/2023

Weight-Loss Drug Stocks Are Soaring. Why There’s More Room to Run.

Weight-loss drugs are becoming increasingly popular and are expected to have a significant impact on the pharmaceutical industry.

9/11/2023

Pharma Market Boom Coming: TBRC Reports Reveal $3 Trillion Industry by 2030 Driven by Disease, Healthcare Advances

9/16/2023

Eli Lilly Poised for Massive Growth with Diabetes, Obesity Drugs and Potential Alzheimer's Blockbuster

9/19/2023

Eli Lilly Sues Providers Over Unauthorized Sales of Diabetes Drug Mounjaro Amid Shortage

9/20/2023

New Obesity Drugs Could Transform Health but Disrupt Major Industries

9/22/2023

Obesity Drug Market Set to Boom as New Medications Gain Traction

The global market for weight-loss drugs is projected to reach $100 billion by 2035, with revenue in the US potentially reaching as high as $70 billion alone.

9/29/2023

Spending on Ads for Diabetes Drugs Jumps 20% in 2022, Totaling Nearly $500 Million

9/29/2023

Structure Therapeutics Stock Jumps on Positive Data for Experimental Obesity Pill

10/3/2023

Lilly to Acquire POINT Biopharma for $1.4 Billion, Gaining Radioligand Cancer Therapies